pharma · Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic
Serana Europe
Serono Europe Limited
Serana Europe clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Pessin, DE
- Founded
- 2014
- Employees
- 20
- Programs
- 8
- Drugs
- 8
- Patents
- 0
Serana Europe projects
6 ClinicalTrials.gov programs sponsored by Serana Europe.
Serana Europe has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Atacicept 75 mg
Serono Europe Limited
Lupus Erythematosus, Systemic
1 trial -
Enpatoran low dose
Serono Europe Limited
Systemic Lupus Erythematosus
1 trial -
M5049
Serono Europe Limited
Coronavirus Disease 2019
1 trial -
M9140
Serono Europe Limited
Solid Tumors
1 trial -
Placebo
Serono Europe Limited
Systemic Lupus Erythematosus
1 trial -
Tepotinib
Serono Europe Limited
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
1 trial
Frequently asked questions
How many clinical projects does Serana Europe have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.